A comparison of the dose–response landscapes for ATM or MDM2-E2F1 combination with AKT in NT_8 and NT_9 revealed how different cancer networks exhibit different dose sensitivities even to treatments that are optimal for both networks. This evidence concerns the gene AKT1 and cancer.